Edwards Lifesciences Total Liabilities 2010-2023 | EW
Edwards Lifesciences total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Edwards Lifesciences total liabilities for the quarter ending March 31, 2023 were $2.589B, a 0.55% increase year-over-year.
- Edwards Lifesciences total liabilities for 2022 were $2.486B, a 6.78% decline from 2021.
- Edwards Lifesciences total liabilities for 2021 were $2.667B, a 0.15% increase from 2020.
- Edwards Lifesciences total liabilities for 2020 were $2.663B, a 13.8% increase from 2019.
Edwards Lifesciences Annual Total Liabilities
(Millions of US $) |
| 2022 |
$2,486 |
| 2021 |
$2,667 |
| 2020 |
$2,663 |
| 2019 |
$2,340 |
| 2018 |
$2,183 |
| 2017 |
$2,710 |
| 2016 |
$1,891 |
| 2015 |
$1,553 |
| 2014 |
$1,332 |
| 2013 |
$1,166 |
| 2012 |
$742 |
| 2011 |
$643 |
| 2010 |
$459 |
| 2009 |
$458 |
Edwards Lifesciences Quarterly Total Liabilities
(Millions of US $) |
| 2023-03-31 |
$2,589 |
| 2022-12-31 |
$2,486 |
| 2022-09-30 |
$2,420 |
| 2022-06-30 |
$2,482 |
| 2022-03-31 |
$2,575 |
| 2021-12-31 |
$2,667 |
| 2021-09-30 |
$2,619 |
| 2021-06-30 |
$2,529 |
| 2021-03-31 |
$2,555 |
| 2020-12-31 |
$2,663 |
| 2020-09-30 |
$2,591 |
| 2020-06-30 |
$2,585 |
| 2020-03-31 |
$2,175 |
| 2019-12-31 |
$2,340 |
| 2019-09-30 |
$2,152 |
| 2019-06-30 |
$2,073 |
| 2019-03-31 |
$2,022 |
| 2018-12-31 |
$2,183 |
| 2018-09-30 |
$2,597 |
| 2018-06-30 |
$2,522 |
| 2018-03-31 |
$2,579 |
| 2017-12-31 |
$2,710 |
| 2017-09-30 |
$2,326 |
| 2017-06-30 |
$2,199 |
| 2017-03-31 |
$2,038 |
| 2016-12-31 |
$1,891 |
| 2016-09-30 |
$1,647 |
| 2016-06-30 |
$1,580 |
| 2016-03-31 |
$1,555 |
| 2015-12-31 |
$1,553 |
| 2015-09-30 |
$1,455 |
| 2015-06-30 |
$1,320 |
| 2015-03-31 |
$1,275 |
| 2014-12-31 |
$1,332 |
| 2014-09-30 |
$1,307 |
| 2014-06-30 |
$1,412 |
| 2014-03-31 |
$1,311 |
| 2013-12-31 |
$1,166 |
| 2013-09-30 |
$1,093 |
| 2013-06-30 |
$760 |
| 2013-03-31 |
$705 |
| 2012-12-31 |
$742 |
| 2012-09-30 |
$660 |
| 2012-06-30 |
$641 |
| 2012-03-31 |
$614 |
| 2011-12-31 |
$643 |
| 2011-09-30 |
$628 |
| 2011-06-30 |
$617 |
| 2011-03-31 |
$573 |
| 2010-12-31 |
$459 |
| 2010-09-30 |
$492 |
| 2010-06-30 |
$524 |
| 2010-03-31 |
$453 |
| 2009-12-31 |
$458 |
| 2009-09-30 |
$512 |
| 2009-06-30 |
$462 |
| 2009-03-31 |
$416 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$51.668B |
$5.382B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
